Liver transplantation for hepatitis D virus/hepatitis B virus coinfection in Italy: An intention-to-treat analysis of long-term outcomes

Patients with hepatitis D virus (HDV)/hepatitis B virus (HBV)-related end-stage liver disease candidates for liver transplantation (LT) have traditionally been regarded as a special population, although their outcomes are controversial. An intention-to-treat (ITT) analysis of long-term outcomes of H...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:American journal of transplantation Ročník 25; číslo 7; s. 1502 - 1514
Hlavní autoři: Angelico, Roberta, Trapani, Silvia, Manzia, Tommaso Maria, Lenci, Ilaria, Grossi, Paolo, Ricci, Andrea, Burra, Patrizia, Andorno, Enzo, Agnes, Salvatore, Bhoori, Sherrie, Baccarani, Umberto, Belli, Luca S., Carrai, Paola, Caccamo, Lucio, Carraro, Amedeo, Cescon, Matteo, Colledan, Michele, Cillo, Umberto, De Carlis, Luciano, De Maria, Nicola, De Simone, Paolo, di Benedetto, Fabrizio, Donato, Maria Francesca, Maria Ettorre, Giuseppe, Ferri, Flaminia, Lanza, Alfonso Galeota, Ghinolfi, Davide, Grieco, Antonio, Gruttadauria, Salvatore, Marenco, Simona, Martini, Silvia, Mazzaferro, Vincenzo, Pellicelli, Adriano, Pinelli, Domenico, Rendina, Maria, Rizzetto, Mario, Romagnoli, Renato, Rossi, Massimo, Russo, Francesco Paolo, Schiadà, Laura, Tandoi, Francesco, Toniutto, Pierluigi, Turco, Laura, Vennarecci, Giovanni, Viganò, Mauro, Vivarelli, Marco, Tisone, Giuseppe, Feltrin, Giuseppe, Nardi, Alessandra, Angelico, Mario
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Elsevier Inc 01.07.2025
Témata:
ISSN:1600-6135, 1600-6143, 1600-6143
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Patients with hepatitis D virus (HDV)/hepatitis B virus (HBV)-related end-stage liver disease candidates for liver transplantation (LT) have traditionally been regarded as a special population, although their outcomes are controversial. An intention-to-treat (ITT) analysis of long-term outcomes of HDV/HBV-coinfected patients waitlisted for LT in Italy, between 2011 and 2020, was performed and compared with HBV-monoinfected LT candidates. Of 1731 HBV-infected LT candidates, 1237 (71.5%) had HBV monoinfection and 494 (28.5%) HDV/HBV coinfection. At listing, HDV/HBV-coinfected patients were significantly younger, listed mainly for decompensated cirrhosis, and with fewer hepatocellular carcinoma (HCC) cases; (26% vs 65.8%; P <.0001) compared with HBV-monoinfected patients. HDV/HBV-coinfected patients showed better 5-year ITT survival (83.2%; 95% CI: 79.4%-83.4%, vs 71.6%; 95% CI: 68.8%-74.2%; P < .0001). ITT-multivariable analysis identified the presence of HCC, advanced recipient age, and high model for end-stage liver disease-Na scores as mortality risk factors. Five years after LT, 99.1% of HDV/HBV-coinfected patients received oral nucleos(t)ide analogs, with immunoglobulins against antigen of the hepatitis B virus in 91.8% of cases. HBV and HDV viral recurrences were 1.1% and 0.2%, respectively, whereas recurrent or de novo HCC were 8.9% and 0.3%, respectively. In Italy, HDV/HBV-coinfected patients waitlisted for LT showed more favorable outcomes compared with HBV-monoinfected patients, both before and after LT. These excellent results, from the largest cohort reported so far, suggest that HDV/HBV-coinfected LT recipients do not represent a risky population and may be considered for simpler long-term antiviral prophylactic strategies.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1600-6135
1600-6143
1600-6143
DOI:10.1016/j.ajt.2025.03.003